Evidence map›Paper›PMID 38124115›Full record

ArticleStem cell research & therapy2023

An evaluation of an open access iPSC training course: "How to model interstitial lung disease using patient-derived iPSCs".

Anja Schweikert, Sarah Kenny, Irene Oglesby, Arlene Glasgow, Chiara de Santi, Ingrid Gensch, Nico Lachmann, Tifenn Desroziers, Camille Fletcher, Deborah Snijders and 3 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Anja Schweikert *Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Sarah Kenny *School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Irene OglesbyDepartment of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Arlene GlasgowDepartment of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin 9, Ireland.
Chiara de SantiSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Ingrid GenschDepartment for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Nico LachmannDepartment for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Tifenn DesroziersLaboratory of Childhood Genetic Disorders Inserm UMR_S933, Armand Trousseau Hospital, Sorbonne University, Paris, France.
Camille FletcherLaboratory of Childhood Genetic Disorders Inserm UMR_S933, Armand Trousseau Hospital, Sorbonne University, Paris, France.
Deborah SnijdersDepartment of Woman and Child Health (SDB), Primary Ciliary Dyskinesia Centre, University of Padova, Padua, Italy.
Nadia NathanLaboratory of Childhood Genetic Disorders Inserm UMR_S933, Armand Trousseau Hospital, Sorbonne University, Paris, France.
Killian HurleyDepartment of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. killianhurley@rcsi.ie.ORCID 0000-0003-4755-5559
COST Open-ILD Group Management Committee
Royal College of Surgeons in Ireland · IEInserm · FRMedizinische Hochschule Hannover · DEUniversity of Padua · ITTrinity College Dublin · IE

Funding

Health Research Board ECSA-2020-011
6 · The paper itself

Abstract

backgroundInterstitial lung diseases (ILD) are a group of rare lung diseases with severe outcomes. The COST Innovator Grant aims to establish a first-of-a-kind open-access Biorepository of patient-derived induced pluripotent stem cells (iPSC) and to train researchers in the skills required to generate a robust preclinical model of ILD using these cells. This study aims to describe and evaluate the effectiveness of a training course designed to train researchers in iPSC techniques to model ILD.

methods74 researchers, physicians and stakeholders attended the training course in Dublin in May 2022 with 31 trainees receiving teaching in practical iPSC culturing skills. The training course learners were divided into the Hands-on (16 trainees) and Observer groups (15 trainees), with the Observers attending a supervised live-streamed experience of the laboratories skills directly delivered to the Hands-on group. All participants were asked to participate in an evaluation to analyse their satisfaction and knowledge gained during the Training Course, with means compared using t-tests.

resultsThe gender balance in both groups was predominantly females (77.4%). The Hands-on group consisted mainly of researchers (75%), whereas all participants of the Observer group described themselves as clinicians. All participants in the Hands-on group were at least very satisfied with the training course compared to 70% of the participants in the Observer group. The knowledge assessment showed that the Hands-on group retained significantly more knowledge of iPSC characteristics and culturing techniques compared to the Observers (* < 0.05; p = 0.0457). A comprehensive learning video detailing iPSC culturing techniques was produced and is included with this manuscript.

conclusionsThe majority of participants were highly or very satisfied with the training course and retained significant knowledge about iPSC characteristics and culturing techniques after attending the training course. Overall, our findings demonstrate the feasibility of running hybrid Hands-on and Observer teaching events and underscore the importance of this type of training programme to appeal to a broad spectrum of interested clinicians and researchers particularly in rare disease. The long-term implications of this type of training event requires further study to determine its efficacy and impact on adoption of iPSC disease modelling techniques in participants' laboratories.

Indexed as

Induced Pluripotent Stem CellsLung Diseases, InterstitialAccess to InformationFemaleHumansMaleCOST Action IG16125Disease modellingEuropean Cooperation in Science and TechnologyInterstitial lung diseaseiPSCsTraining course

Identifiers

PMID38124115
PMCPMC10734099
OpenAlexW4389992502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.